Corvus Pharmaceuticals Inc diskutieren
Corvus Pharmaceuticals Inc
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
7,11 €
-3,00 %
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at LADENBURG THALM/SH SH from $12.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $11.00 price target on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for CRVS provided by MarketBeat
Neueste Beiträge
Roth_Capital in Gran Tierra Energy Inc. diskutieren